Covid 19 Research using Clinical Trials (Home Page)
Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation
Correlated Drug Terms (0)
|
Name (Synonyms) |
Correlation |
Correlated MeSH Terms (0)
|
Name (Synonyms) |
Correlation |
Correlated HPO Terms (0)
|
Name (Synonyms) |
Correlation |
There is one clinical trial.
Clinical Trials
According to recent data, death rate is more than 20% for 75 years old hospitalized patients
and older.
In case of aggravation, according to the latest observations, if they are refused for
mechanical ventilation in intensive care, their death rate could reach 60% even for patients
without comorbidity.
Apart from an increase in oxygen therapy, no specific treatment is currently proposed.
The control of the inflammatory component seems to be a key element to be able to influence
the patients' health evolution.
Polyvalent intravenous immunoglobilins have immunomodulatory and anti-inflammatory properties
with a favorable safety profile for these elderly patients and several clinical cases lead to
positive impact in the caring for Covid patients.
This study objective is evaluation of the efficacy of polyvalent IVIg in combination with the
standard management of patients aged 75 and over with SARSCov2 infection with acute
respiratory failure (saturation ≤ 95%) requiring oxygen therapy> 5 L / min (i.e. patients
considered as moderate to severe ARDS according to the Berlin definition, Pa02 / Fi02≤200)
and disqualified from a care in the ICU.
Primary Outcomes
Measure: Mortality Time: Day 14
Secondary Outcomes
Measure: Total number of days of full hospitalization Time: 3 and 6 months
Measure: Duration of oxygen therapy Time: 3 and 6 months
Measure: Ferritin level in the blood Time: 3 and 6 months
Measure: CRP level in the blood Time: 3 and 6 months
Measure: LDH level in the blood Time: 3 and 6 months
Measure: Lymphocyte level in the blood Time: 3 and 6 months
Measure: PNN level in the blood Time: 3 and 6 months
Measure: platelet level in the blood Time: 3 and 6 months
Measure: WHO performance index Time: 3 and 6 months
Measure: WHOQOL-OLD questionnaire Time: 3 and 6 months
Measure: Lung function by pulmonary computed tomography Time: 3 and 6 months
Measure: Lung function by EFR Time: 3 and 6 months
Measure: Mortality Time: 3 and 6 months
Measure: Readmission Rates Time: 3 and 6 months
No related HPO nodes (Using clinical trials)